

**List of insider information under Art. 7 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 regarding market abuse (Regulation on market abuse) on the circumstances that occurred in the second quarter of 2023**

**11 January 2023**

**Sales revenues for December 2022**

Sofia, Bulgaria, January 11, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for December 2022 the Company recorded an increase in sales of 19% compared to the same month of the previous year, incl. 14% increase in domestic sales and 21% increase in export sales.

For 2022 the revenues from sales of products increase by 15%, incl. 10% increase of sales for the domestic market and 19% increase in export sales.

**12 January 2023**

**NOTIFICATION**

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with warrants of “Sopharma” AD:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
11.01.2023	Sell	540,00	0,54

**13 January 2023**

**Received corrected tender offer addressed to the shareholders of "Sopharma" AD from "Donev Investments Holding" AD**

Sofia, Bulgaria, January 13, 2023 – According to the requirements of art. 100t of LPOS, the Board of Directors of "Sopharma" AD (SFA: "BFB - Sofia", SPH: Warsaw Stock Exchange) announces that on January 13, 2023, "Sopharma" AD received a corrected tender offer, registered with the Financial Supervision Commission from "DONEV INVESTMENTS HOLDING" AD - a shareholder directly owning 37,600,000 ordinary, non-available shares with voting rights, representing 27.89% of the capital and votes in the GMS of "SOPHARMA" AD, on the basis of art. 149b of the Law on the Public Offering of Securities for the purchase of shares from the remaining shareholders of "SOPHARMA" AD.

The essential conditions of the tender offer are:

Information about trade offeror:

The tenderer is "DONEV INVESTMENTS HOLDING" AD, a company established and operating as a joint-stock company under Bulgarian legislation, with its registered office and management address: Sofia, p.c. 1000, Vazrazhdane district, "Positano" street No. 12; phone: +359 (2) 9880016; electronic address (e-mail) ivandonev@dih.bg; electronic page on the Internet (web-site): none. "DONEV INVESTMENTS HOLDING" AD is registered in the Commercial Register and the register for non-profit legal entities maintained by the Registration Agency ("Commercial Register") with EIC 831915121.

The object of the Proposer is as follows: participation in the capital of other commercial companies; acquisition and management of investments in other companies; acquisition of financial assets for the purpose of trading, raising of funds by issuing securities and subsequent investment of the funds raised, investment management and investment operations, consultancy services, translation activities and all activities in the territory of the country or abroad not prohibited by law.

The name of the Offeror is "DONEV INVESTMENTS HOLDING" AD. The company was incorporated under the name "Sofia" AD, and subsequently on May 14, 2008, the current name of the company - "DONEV INVESTMENTS HOLDING" AD - was entered in the Commercial Register at the Registration Agency.

As of the date of registration of the corrected Trade Offer with the Commission for Financial Supervision - January 13, 2023, "DONEV INVESTMENTS HOLDING" AD has capital in the amount of BGN 29,500,000, which is fully paid up.

The identification code of the legal entity (Legal Entity Identifier code) is 529900M68G247LNXVB33.

"DONEV INVESTMENTS HOLDING" AD is managed by a Board of Directors (BoD) in the following composition:

- Phd Ognyan Ivanov DONEV, business address: Sofia, p.c. 1000, Vazrazhdane District, 12 Positano Str. - Chairman of the Board of Directors;
- Ivan Ognyanov DONEV, business address: Sofia, p.c. 1000, Vazrazhdane District, 12 Positano Str. – member of the Board of Directors and Executive Director;
- Rositsa Dimcheva DONEVA, business address: Sofia, p.c. 1000, Vazrazhdane District, 12 Positano Str - member of the Board of Directors.

According to its charter, "DONEV INVESTMENTS HOLDING" AD is represented by its Executive Director - Ivan Ognyanov Donev.

Shareholders holding directly and/or through related persons more than 5 percent of the votes in the General Meeting of the Proposer are as follows:

Phd Ognyan Ivanov Donev - shareholder who, as of the date of registration of the corrected Trade Offer with the Commission for Financial Supervision – January 13, 2023, directly owns 29,346,300 shares or 99.48% of the capital and votes in the GMS of "DONEV INVESTMENTS HOLDING" AD.

The business address of Mr. Phd Ognyan Ivanov Donev is the city of Sofia, p.c. 1000, Vazrazhdane district, 12 Positano Str.

Phd Ognyan Ivanov Donev exercises control over "DONEV INVESTMENTS HOLDING" AD in the sense of § 1c, item 1 of the Additional Provisions of the Commercial Law and § 1, item 14 of the Additional Provisions of the Law on the Public Offering of Securities, as it directly owns more than 50 percent of the number of votes in the General Meeting of Shareholders of "DONEV INVESTMENTS HOLDING" AD.

Number of voting shares that the offeror does not own

"DONEV INVESTMENTS HOLDING" AD does not own (directly, through related parties or indirectly pursuant to Art. 149, para. 2 of the Civil Code) 89,865,700 ordinary, non-cash, registered, freely transferable shares with ISIN BG11SOSOBT18, representing 66.67% of the capital and from the votes in the General Meeting of the shareholders of "SOPHARMA" AD. In accordance with the decision taken by the Offeror's Board of Directors dated October 28, 2022, the Offeror intends to increase its share in the Company's capital by acquiring directly and through related parties more than 1/3, namely - up to 41.49% of the votes in the General Meeting of the Company's shareholders, by purchasing according to the order of the Commercial Offer under Art. 149b of the LPOS, addressed to all other shareholders of

"SOPHARMA" AD of up to 11,000,000 ordinary, bearer, registered, freely transferable shares, with ISIN BG11SOSOBT18, representing 8.16% of the capital and votes in the General Meeting of Shareholders of "SOPHARMA" AD.

The offeror's strategic plans regarding "Sopharma" AD

According to the information presented in the tender offer, the Proposer's strategic plan for Sopharma AD (the Company) includes the following key points:

- to increase sales of its existing portfolio, as well as by adding new products in categories in which the Company has a strategic interest. To this end, the company is actively exploring various opportunities to acquire products that would complement and diversify its own portfolio;
- to achieve a phased transformation of its production processes and capacities through the optimization of the Company's production capacity through the purchase and modernization of new machinery and equipment and the transfer of production activities and technologies. In addition to this, a strategy has been developed and is in the process of being implemented to optimize the processes of planning, supplies, production, distribution through active management along the supply chains. This would allow new business segments to develop, such as potential contract manufacturing;
- continued operation of the production in full compliance with the good manufacturing practices adopted in the EU;
- to diversify the activity of its distribution business, which is carried out through the subsidiary "SOPHARMA TRADING" AD. In 2015, "SOPHARMA TRADING" AD launched the development of its own retail pharmacy concept under the SOpharmacy brand. In 2017, the company acquired the PharmaStor chain of pharmacies, which subsequently went under the SOpharmacy brand. In October 2020, the company acquired the companies from the "SCS Franchise" AD group, as well as "Sanita Franchising" AD. As a result of the transaction, "SOPHARMA TRADING" AD acquired over 150 pharmacies across the country under the Sanita, Ceiba and SCS brands. The plans foresee their transition under the SOpharmacy brand, a process that began in 2021. In the future, "SOPHARMA TRADING" AD aims to continue to strengthen its position on the Bulgarian market by expanding its pharmacy network in the country;
- to implement new technologies to support the automation of business processes in the SOPHARMA GROUP ("the Group");
- to deepen the operational synergy between the companies in the Group, both within the segments themselves and between interconnected segments such as manufacturing and distribution of pharmaceutical products;
- to develop its personnel through training in order to increase qualifications and competencies and to preserve and maintain the reputation of a preferred employer with opportunities for career development in the segments of the Group, as well as to work closely with specialized higher education institutions and offer a career start to personnel;
- to implement a diversity policy in the Group with the aim of creating a working environment free from prejudice, cultivating an atmosphere of respect and mutual trust, fostering a corporate culture of mutual respect and valuing each individual. Managers and employees carry out their activities professionally, impartially, with dignity and integrity, avoiding conflicts of interest;
- to implement a green policy in order to reduce the carbon footprint of the companies in the Group by using energy from renewable sources.

The implementation of the strategy depends on the influence and development of the following main risk factors, characteristic of the profile of "SOPHARMA" AD and the businesses in which the companies of the Group operate:

- non-systemic risks specific to the Group - risks from the influence of epidemics and pandemics; risks arising from dependence on the development of the world economy and trade; risk of political instability in traditional markets and regions, military action and/or imposed sanctions; risks related to fraud and abuse; risks related to the regulatory framework governing the pharmaceutical business and environmental protection; risks related to attracting and retaining experienced and qualified personnel; credit, liquidity, currency and interest rate risk. Each of these risks affects the Group's segments to a different extent;
- systemic risks related to the market and the macro environment in which companies operate. These risks cannot be managed and controlled by the Group.

The Proposal is not expected to have an impact on the employees of "SOPHARMA" AD (including the employees of the subsidiaries) and "DONEV INVESTMENTS HOLDING" AD for a period of three years after the conclusion of the transaction. There is no change in the place of business of "SOPHARMA" AD (including the subsidiaries) and "DONEV INVESTMENTS HOLDING" AD.

Offer price per share

The proposed price of the tender offer is BGN 4.50 per share and is higher than the average weighted market price of the shares for the last 6 months, before the registration of the Tender Offer, which is BGN 4.485.

Each shareholder - the addressee of the proposal can accept it within the period specified in it, by submitting an application for acceptance according to the model. The price of the purchased shares shall be paid by the trading offeror, through IP "Karol" AD within 7 working days after the expiration of the period for acceptance of the offer, according to the instructions for the method of payment by the shareholder who accepted the offer.

The Financial Supervision Commission (FSC) has not taken a position on the submitted corrected draft of the tender offer.

**27 January 2023**

**"Sopharma" AD submitted for approval to the Financial Supervision Commission for an Agreement for conversion by merger of the subsidiary company "Biopharm-engineering" AD**

Sofia, Bulgaria, January 27, 2023 – According to the requirements of art. 100t of LPOS, "Sopharma" AD (SFA: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that in compliance with the decision of the Board of Directors of "Sopharma" AD dated 26.10.2022, the Company submitted for approval to the Financial Supervision Commission an Agreement for conversion by merger of the subsidiary company "Biopharm-engineering" AD, UIC: 119055339 in "Sopharma" AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 of the Law on Public Offering of Securities.

**1 February 2023**

**Dissimination of monthly sales information**

Sofia, Bulgaria, February 1, 2023 – According to the requirements of art. 100t of LPOS, "Sopharma" AD (SFA: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that in order to more accurately present and prevent deviations in the published information concerning the

Company's monthly sales data, the Board of Directors of "Sopharma" AD adopted a decision to extend the deadline for the publication of the relevant information until the 20th of the month following the reporting period.

## **6 February 2023**

### **Sales revenues for January 2023**

Sofia, Bulgaria, February 6, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for January 2023 the Company recorded an increase in sales of 33% compared to the same month of the previous year, incl. 27% decrease in domestic sales and 174% increase in export sales.

## **21 February 2023**

### **Notification for share participation from “Donev investments holding” AD**

Sofia, Bulgaria, February 21, 2023 – According to the requirements of Art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that today the Company received a notification for participation from “Donev investments holding, UIC 831915121. As a result of acquired shares following a tender offer made by "Donev Investments Holding" AD to the shareholders of "Sopharma" AD, "Donev Investments Holding" AD increases its direct participation in the capital of the Company to 35.24%, crossing the threshold of 35%. The tender offer was accepted by 31 shareholders (a total of 9,902,092 capital shares) of Sopharma AD.

## **21 February 2023**

### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by “Donev Investments Holding” AD related to Ognian Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
17.02.2023	Buy	9 902 092,00	4,50

**21 February 2023**

**NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by “Donev Investments Holding” AD related to Ognian Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
20.02.2023	Pledge of shares	14 500 000,00	1,00

**21 February 2023**

**Notification for share participation from “Telso” AD**

Sofia, Bulgaria, February 21, 2023 – According to the requirements of Art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that today the Company received a notification for participation from “Telso” AD, UIC 131176385. As a result of the accepted tender offer, "Telso" AD is reduced below the threshold from 5% to 1.44% in the capital of "Sopharma" AD.

**21 February 2023**

**NOTIFICATION**

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
17.02.2023	Sell as a result of a tender offer	5 000 000,00	4,50

**20 March 2023**

**Sales revenues for February 2023**

Sofia, Bulgaria, March 20, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for February 2023 the Company recorded an increase in sales of 20% compared to the same month of the previous year, incl. 41% increase in domestic sales and 10% increase in export sales. For the first two months of 2023, sales increased by a total of 21%, incl. same level of domestic sales and 42% increase in export sales.

**20 April 2023**

### **Sales revenues for March 2023**

Sofia, Bulgaria, April 20, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for March 2023 the Company recorded an increase in sales of 127% compared to the same month of the previous year, incl. 3% increase in domestic sales and 426% increase in export sales due to the low base in the previous period due to the collapse of sales in the main markets as a result of the conflict between Russia and Ukraine.

For the first three months of 2023, sales increased by a total of 45%, incl. 1% increase of sales for the domestic market and 97% increase in export sales.

**21 April 2023**

The Board of Directors hereby convenes a General Meeting of the holders of warrants of “SOPHARMA” AD with the unique identification code SFAGMW02062023 to be held on 2 June 2023 at 14:00 hours (11:00 UTC) at the Company's headquarters in Sofia city with place of holding: 5 Lachezar Stanchev Str., Ground Floor, Sopharma Business Towers, Sopharma Event Center, and in the absence of a quorum on that date - on 23 June 2023 at the same location, with the same starting time and agenda.

The General Meeting of Warrant holders scheduled to be held on June 2, 2023 be held with the following agenda and with the following proposed resolutions by the Board of Directors:

Substantive issues:

1. Adoption of a Report on the movement of the price of ordinary shares of "SOPHARMA" AD on the regulated market, organized by the "Bulgarian Stock Exchange" AD, for the last 12 months; Draft decision: The general meeting of warrant holders accepts a Report on the movement of the price of ordinary shares of "SOPHARMA" AD on the regulated market, organized by the "Bulgarian Stock Exchange" AD, for the last 12 months;
2. Adopting a decision to exercise the warrants' rights. Draft decision: The general meeting of the holders of warrants with ISIN BG9200001212 adopts a decision to exercise the rights to subscribe shares from a future increase in the capital of "SOPHARMA" AD, by issuing 44 925 943 number of ordinary, registered, dematerialized shares, with the right to vote, with a nominal value of BGN 1 each and an issue value of BGN 4.13 per share, provided that the shares from the increase are subscribed solely by the warrant holders;
3. Requesting that the Board of Directors adopts a decision on a conditional capital increase. Draft decision: Requesting that the Board of Directors adopts a decision on a capital increase under the provisions of the Company's Articles of Association, Art. 195 of the Commercial Code and in accordance with art. 113, para. 2, item 2 of the LPOS, in which the warrant holders can exercise their rights under item 2 of the agenda, and under the terms and conditions described in the Prospectus for the public offering of warrants, confirmed with a Decision of the Financial Supervision Commission № 804 – E/04.11.2021.

**28 April 2023**

### **Invitation and materials for a General shareholders meeting**

Sopharma AD-Sofia presented an invitation to convene a Regular General Meeting of Shareholders and materials for a General Meeting of Shareholders, which will be held on 02-06-2023. from 11:00 a.m. at 1000, Lachezar Stanchev 5, with the following agenda:

1. Approval of the Annual Report of the Board of directors on the company's activities in 2022; Draft decision: The AGM approves the Annual Report of the Board of directors on the Company's activities in 2022;
2. Approval of the Annual report of the Investor Relations Director for 2022; Draft decision: The AGM approves the Annual report of the Investor Relations Director for 2022;
3. Approval of the Audited Annual Individual Financial Statement of the Company for 2022; Draft decision: The AGM approves the Audited Annual Individual Financial Statement of the Company for 2022;
4. Approval of the Audited Annual Consolidated Financial Statement of the Company for 2022; Draft decision: The AGM approves the audited Annual Consolidated Financial Statement of the Company for 2022;
5. Approval of the Auditor's report on the audit of the Annual Individual Financial Statements of the Company for the year 2022; Draft decision: The AGM approves the Auditor's report on the audit of the Annual Individual Financial Statements of the Company for the year 2022;
6. Approval of the Auditor's report on the audit of the Annual Consolidated Financial Statements of the Company for the year 2022; Draft decision: The AGM approves the Auditor's report on the audit of the Annual Consolidated Financial Statements of the Company for the year 2022;
7. Approval of a decision for distribution of the Company's profit realized in 2022 and retained earnings from previous periods; Draft decision: The AGM approves the proposal of the Board of Directors that the net financial result in its full amount of BGN 39 429 437,38 (thirty-nine million four hundred twenty-nine thousand four hundred thirty-seven and 38 stotinki) be distributed as a cash dividend to the shareholders, as follows : to be distributed to the shareholders a gross dividend in the amount of BGN 0,60 per share (sixty stotinki), with the amount up to the full amount of the dividend above the financial result for 2022 being at the expense of the undistributed profit of the Company from previous years in the amount of BGN 757 395,39 (seven hundred fifty-seven thousand three hundred ninety-five and 39 stotinki) and from the Company's additional reserves. The right to receive a dividend belongs to the persons entered in the registers of the Central Depository (CD) as shareholders on the 14th day after the day of the General meeting, at which the annual financial report was adopted and a decision was taken on the distribution of profit. The company must ensure the payment to the shareholders of the dividend voted at the general meeting within 60 days of its holding. The costs of paying the dividend are at the expense of the company. The payment of the dividend is carried out with the assistance of the CD. Shareholders with open accounts with an investment intermediary will receive their dividend through the respective investment intermediary, and those with personal CD accounts will be able to receive their dividend from the branches of "Eurobank Bulgaria" AD (Postbank) in the country;
8. Approval of the Audit Committee's report in 2022; Draft decision: The AGM approves the Audit Committee's report on its activities in 2022;
9. Approval of a decision to discharge the members of the Board of Directors for their activity in 2022; Draft decision: The AGM releases the members of the Board of Directors from responsibility for their activities in 2022;
10. Election of the Audit Committee of the Company due to the expiration of the term of the current members: Draft decision: The AGM re-elects the current members of the Audit Committee of the company for a new term of three years, according to the proposal of the Chairman of the Board of Directors of the company enclosed in the materials for the AGM;
11. Election of a registered auditor of the Company for 2022; Draft decision: The AGM elects a registered auditor to verify and certify the Annual Financial Statements of the Company



for 2022, in accordance with the proposal of the the Audit Committee, enclosed in the materials for the AGM;

12. Approval of the Report of the Board of directors on the implementation of the Remuneration Policy for the members of the Board of directors of the Company for 2022; Draft decision: The General Meeting approves the Report of the Board of directors on the implementation of the Remuneration Policy of the members of the Board of directors of the Company for 2022;

13. Determination of the remuneration of the members of the Board of directors for 2023; Draft decision: The remuneration of the members of the Board of directors and the Executive Director remains unchanged;

14. Approval of a decision under art. 24, para 3, letter B of the Articles of Association of the Company; Draft decision: Pursuant to art. 24, para 3, letter B of the Articles of Association, the Executive Director of the Company shall be paid an additional remuneration of 1% (one percent) of the amount of profit realized in 2022 according to the approved Annual Financial report and the Remuneration Policy of the Company;

15. Approval of a decision to determine a percentage of the profit realized in 2022 to be distributed among the members of the senior management team of the Company, subject to the requirements of art. 26a, item 12 of the Articles of Association of the Company; Draft decision: The General Meeting adopts a decision that of 2% (two percent) of the profit realized in 2022 will be distributed among the members of the company's senior management team, subject to the requirements of art. 26a, item 12 of the Articles of Association of the Company;

16. Approval of the Substantiated Report of the Board of directors for transactions within the scope of art. 114, para 1 of the LPOS; Draft decision: AGM approves the Substantiated Report of the Board of directors for transactions within the scope of art. 114, para 1 of the LPOS;

17. Authorization within the meaning of art. 114, para 1 of the LPOS on a transaction between “Sopharma” AD and “Telecomplect” AD - Section One of the Substantiated Report; Draft decision: The General Meeting of Shareholders of “SOPHARMA” AD to approve and authorize the persons who manage and represent the public company for the conclusion of a Lease Agreement between “SOPHARMA” AD as a assigner and “TELECOMPLECT” AD as a contractor;

18. Miscellaneous.

## **22 May 2023**

### **Sales revenues for April 2023**

Sofia, Bulgaria, May 22, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for the month of April 2023, "Sopharma" AD realized a decrease in sales of 22% compared to the same month of the previous year, including 5% decrease of domestic sales and 31% decrease of export sales.

For the four months of 2023, sales increased by a total of 24% - maintaining domestic sales and 47% growth of export sales.

## **1 June 2023**

### **Analysis of potential acquisition opportunities on the territory of the Republic of Serbia**

Sofia, Bulgaria, June 1, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies

that at its meeting the Board of Directors decided to conduct a detailed analysis of potential opportunities for acquisition of shares in the capital of companies engaged in the production and/or marketing of medicinal products, food supplements, medical devices and/or other goods of importance to human health on the territory of the Republic of Serbia. The Board of Directors has authorized the representatives of the Company to carry out all necessary legal and factual actions related to the evaluation, investigation and initial negotiations for the implementation of a possible acquisition of a joint participation and/or a majority stake in the capital of such companies.

**2 June 2023**

### **Notification on the terms and conditions for distribution of the dividend**

Sofia, Bulgaria, June 2, 2023 – In accordance with the requirements of art. 115c, para. 4 of LPOS “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies all shareholders of the Company about the decision of the AGM of “Sopharma” AD that took place on June 2, 2023 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:

The AGM approves the proposal by the Board of Directors for the distribution of gross dividend at the amount of 0.60 BGN /sixty stotinki / per share.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the AGM on which the Annual Financial Report was approved and the decision for dividend was taken, namely June 16, 2023 (record date) – ex dividend date June 15, 2023. The starting date for dividend payment is July 31, 2023.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary – through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of “Eurobank EFG – Bulgaria” AD /Postbank/ in the country.

**2 June 2023**

### **Notification for dividend payment**

The AGM approves the proposal by the Board of Directors for the distribution of gross dividend at the amount of 0.60 BGN /sixty stotinki / per share.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the AGM on which the Annual Financial Report was approved and the decision for dividend was taken, namely June 16, 2023 (record date) – ex dividend date June 15, 2023. The starting date for dividend payment is July 31, 2023.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary – through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of “Eurobank EFG – Bulgaria” AD /Postbank/ in the country.

**5 June 2023**

### **NOTIFICATION**

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
01.06.2023	Sell	5 000,00	5,90
01.06.2023	Sell	2 500,00	5,90
01.06.2023	Sell	300,00	5,90
01.06.2023	Sell	4 700,00	5,90
01.06.2023	Sell	5 000,00	5,90
01.06.2023	Sell	5 000,00	5,90
01.06.2023	Sell	3 000,00	5,90
01.06.2023	Sell	400,00	5,90
01.06.2023	Sell	85,00	5,90
01.06.2023	Sell	4 515,00	5,90
01.06.2023	Sell	5 000,00	5,90
01.06.2023	Sell	485,00	5,90
01.06.2023	Sell	3 650,00	5,90
01.06.2023	Sell	865,00	5,90
01.06.2023	Sell	5 000,00	5,90
01.06.2023	Sell	4 135,00	5,90
01.06.2023	Sell	865,00	5,90
01.06.2023	Sell	5 000,00	5,90
01.06.2023	Sell	4 135,00	5,90
01.06.2023	Sell	865,00	5,90
01.06.2023	Sell	1 142,00	5,90
01.06.2023	Sell	3 858,00	5,90
01.06.2023	Sell	5 000,00	5,90
01.06.2023	Sell	1 142,00	5,90
01.06.2023	Sell	155,00	5,90
01.06.2023	Sell	3 703,00	5,90
01.06.2023	Sell	5 000,00	5,90
01.06.2023	Sell	1 297,00	5,90
01.06.2023	Sell	3 703,00	5,90
01.06.2023	Sell	5 000,00	5,90
01.06.2023	Sell	1 097,00	5,90
01.06.2023	Sell	1 000,00	5,90
01.06.2023	Sell	2 403,00	5,90
01.06.2023	Sell	200,00	5,94
01.06.2023	Sell	500,00	5,96

**5 June 2023**

### **NOTIFICATION**

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
01.06.2023	Sell	230 000,00	0,52

**5 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
20.06.2022	Buy	2 970,00	0,97
20.06.2022	Buy	3 030,00	0,97

**5 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
01.06.2023	Pledge of shares	4 900 000,00	1,00

**5 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mr Alexandar Tchaoushev, Member of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
01.06.2023	Buy	1 900	5,90
01.06.2023	Buy	5 000	5,90
01.06.2023	Buy	5 000	5,90
01.06.2023	Buy	4 700	5,90
01.06.2023	Buy	300	5,90
01.06.2023	Buy	3 000	5,90
01.06.2023	Buy	400	5,90
01.06.2023	Buy	2 500	5,90

01.06.2023	Buy	4 135	5,90
01.06.2023	Buy	5 000	5,90
01.06.2023	Buy	4 135	5,90
01.06.2023	Buy	3 858	5,90
01.06.2023	Buy	5 000	5,90
01.06.2023	Buy	1 142	5,90
01.06.2023	Buy	3 703	5,90
01.06.2023	Buy	5 000	5,90
01.06.2023	Buy	1 297	5,90
01.06.2023	Buy	3 703	5,90
01.06.2023	Buy	5 000	5,90
01.06.2023	Buy	200	5,90
01.06.2023	Buy	1 000	5,90
01.06.2023	Buy	4 515	5,90
01.06.2023	Buy	5 000	5,90
01.06.2023	Buy	865	5,90
01.06.2023	Buy	2 200	5,90
01.06.2023	Buy	5 000	5,90
01.06.2023	Buy	485	5,90
01.06.2023	Buy	5 000	5,90
01.06.2023	Buy	865	5,90
01.06.2023	Buy	1 097	5,90

**5 June 2023**

### NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
01.06.2023	Pledge of shares	4 900 000	1,00

**5 June 2023**

Sofia, Bulgaria, June 5, 2023 - Pursuant to the requirements of Article 100t of the Securities Act, Sopharma AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) announces that at its meeting the Board of Directors of the Company resolved to increase the capital on the condition that the shares from the increase are subscribed by the warrant holders, based on a resolution legally adopted at the General Meeting of Warrantholders (GMW) on June 2, 2023. This notification is not a notification pursuant to art. 89t of the Law on Public Offering of Securities.

The expected timetable for implementing the increase is as follows:

Date of disclosure of the announcement under Article 89t(2) of the Securities Act on the website [www.x3news.com](http://www.x3news.com), on the websites of Sopharma AD and the authorised investment intermediary Sofia International Securities AD 24 August 2023

Commencement date for the exercise of the warrants 1 September 2023

Closing date for payment and subscription of shares 26 September 2023

Registration of the issue of new shares and capital increase in the Commercial Register \* 2 October 2023

Registration of the new shares in investors' accounts with the Central Depository \* 10 October 2023

Registering the capital increase in the FSC register under art. 30 from the Law on the Financial Supervision Commission \* 17 or 19 October 2023

Commencement of trading in the new shares on the BSE \* 30 October 2023

\* in accordance with the deadlines of the relevant institution

**6 June 2023**

### NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
05.06.2023	Buy	3 217,00	1,18
05.06.2023	Buy	1 390,00	1,18
05.06.2023	Buy	2 510,00	1,18
05.06.2023	Buy	3 000,00	1,15
05.06.2023	Buy	5 000,00	1,12
05.06.2023	Buy	4 000,00	1,12
05.06.2023	Buy	1 000,00	1,12
05.06.2023	Buy	20 000,00	1,12
05.06.2023	Buy	30 000,00	1,11
05.06.2023	Buy	5 000,00	1,12

**6 June 2023**

### NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.06.2022	Sell	500,00	6,18
05.06.2022	Sell	300,00	6,18
05.06.2022	Sell	1 000,00	6,16
05.06.2022	Sell	200,00	6,18

**6 June 2023**

**NOTIFICATION**

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.06.2023	Sell	430,00	6,20
05.06.2023	Sell	1 000,00	6,20
05.06.2023	Sell	80,00	6,22
05.06.2023	Sell	180,00	6,18
05.06.2023	Sell	3 570,00	6,20
05.06.2023	Sell	10 000,00	6,20
05.06.2023	Sell	10 000,00	6,20
05.06.2023	Sell	10 000,00	6,20
05.06.2023	Sell	50 000,00	6,20
05.06.2023	Sell	50 000,00	6,18
05.06.2023	Sell	49 820,00	6,18

**7 June 2023**

**NOTIFICATION**

"Sopharma" AD informs that according to Art. 3 § 26a and Art. 19 § 1 a received a notification from Rositsa Doneva, a person closely related to Ognian Ivanov Donev, that Mrs. Doneva carried out the following transactions with shares of "Sopharma" AD:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
05.06.2023	Buy	20 000	1,11
05.06.2023	Buy	30 000	1,11
05.06.2023	Buy	15 000	1,11
05.06.2023	Buy	10 000	1,11

**8 June 2023**

**NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
07.06.2023	Sell	2 000	1,16
07.06.2023	Sell	8 000	1,16
07.06.2023	Sell	100 000	1,16
07.06.2023	Sell	2 000	1,16

07.06.2023	Sell	5 000	1,13
07.06.2023	Sell	5 000	1,13
07.06.2023	Sell	5 000	1,12
07.06.2023	Sell	9 000	1,12

**8 June 2023**

### NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
07.06.2023	Buy	2 000,00	1,16
07.06.2023	Buy	2 000,00	1,16
07.06.2023	Buy	8 000,00	1,16
07.06.2023	Buy	10 000,00	1,16
07.06.2023	Buy	100 000,00	1,16
07.06.2023	Buy	4 000,00	1,16
07.06.2023	Buy	1 000,00	1,16
07.06.2023	Buy	5 000,00	1,13
07.06.2023	Buy	5 000,00	1,13
07.06.2023	Buy	10 000,00	1,13
07.06.2023	Buy	10 000,00	1,13
07.06.2023	Buy	500,00	1,13
07.06.2023	Buy	1 500,00	1,13
07.06.2023	Buy	1 000,00	1,15
07.06.2023	Buy	5 000,00	1,12
07.06.2023	Buy	9 000,00	1,12
07.06.2023	Buy	272,00	1,12

**9 June 2023**

### NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
08.06.2023	Sell	1 000	1,11
08.06.2023	Sell	4 000	1,11
08.06.2023	Sell	1 000	1,12
08.06.2023	Sell	1 000	1,12
08.06.2023	Sell	900	1,12
08.06.2023	Sell	50 000	1,12
08.06.2023	Sell	10 000	1,12



08.06.2023	Sell	5000	1,12
08.06.2023	Sell	3000	1,13
08.06.2023	Sell	3000	1,13
08.06.2023	Sell	3000	1,13

**9 June 2023**

### NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
08.06.2023	Buy	4 000,00	1,11
08.06.2023	Buy	50 000,00	1,12
08.06.2023	Buy	10 000,00	1,12
08.06.2023	Buy	5 000,00	1,12
08.06.2023	Buy	3 000,00	1,13
08.06.2023	Buy	3 000,00	1,13
08.06.2023	Buy	3 000,00	1,13
08.06.2023	Buy	10,00	1,13

**9 June 2023**

**A transaction concluded by the subsidiary "Pharmalogistika" AD under Art. 114, para. 3 of the Law on Public Offering of Securities requiring prior approval of the public company**

Sofia, Bulgaria, June 9, 2023 - Pursuant to the requirements of Article 100t of the LPOS and in conjunction with Article 114, par. 9 of the LPOS, "Sopharma" AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) hereby informs that following a request made to the parent company "Sopharma" AD by the subsidiary "Pharmalogistika" AD and the consent given by the Board of Directors on 06.06.2023, today the subsidiary concluded the following transaction falling within the scope of Art. 114 para. 3 of the Securities Act:

1. "Pharmalogistika" AD, UIC 130959211, as a landlord, concluded a contract for the lease of an investment property with address in the town of Sofia, blvd. Rozhen № 16, with a total rental area of 2 985.25 sq.m. for a monthly rental price of BGN 17 190 (seventeen thousand one hundred and ninety) excluding VAT for a period of 3 /three/ years to "Sofprint Group" AD, UIC 175413277.

**A) Interested parties participation:**

Tsvetanka Zlateva and Boris Borisov are members of the Board of Directors of "Pharmalogistika" AD and of "Sofprint Group" AD - grounds for interest under art. 114, par. 7, item 3 of the Law on Public Offering of Securities.

**B) Transaction Value:**

The market price of the rented property has been determined in accordance with a market valuation prepared by an independent valuer under Article 5 of the Independent Valuers Act. According to the market valuation so prepared, the monthly rental market price of the real estate is BGN 17 190 excluding VAT.

C) Assessment of the applicability of the conditions under Art. 114, para. 3, item 1 of the Law on Public Offering of Securities:

The value of the described transaction exceeds the threshold under Art. 114, para. 3, item 1, letter (b) of the Law on Public Offering of Securities and thus requires a preliminary approval by the parent public Company.

D) Assessment of the applicability of Article 114(6) of the Law on Public Offering of Securities:

The hypothesis of Article 114 paragraph 6 of the Law on Public Offering of Securities does not apply to this transaction.

**13 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
12.06.2023	Sell	1 000	1,12
12.06.2023	Sell	1 000	1,11
12.06.2023	Sell	20 000	1,11

**13 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
12.06.2023	Buy	1 000,00	1,11
12.06.2023	Buy	20 000,00	1,11

**13 June 2023**

### **NOTIFICATION**

"Sopharma" AD informs that according to Art. 3 § 26a and Art. 19 § 1 a received a notification from Rositsa Doneva, a person closely related to Ognian Ivanov Donev, that Mrs. Doneva carried out the following transactions with shares of "Sopharma" AD:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
12.06.2023	Buy	1 000	1,14
12.06.2023	Buy	1 000	1,12

**14 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
13.06.2023	Sell	2 000	1,11
13.06.2023	Sell	1 000	1,11
13.06.2023	Sell	10 000	1,11
13.06.2023	Sell	5 000	1,11
13.06.2023	Sell	5 000	1,11
13.06.2023	Sell	5 000	1,11
13.06.2023	Sell	5 000	1,11
13.06.2023	Sell	5 000	1,11
13.06.2023	Sell	5 000	1,11
13.06.2023	Sell	8 000	1,11
13.06.2023	Sell	5 000	1,11
13.06.2023	Sell	3 000	1,11
13.06.2023	Sell	5 000	1,11
13.06.2023	Sell	5 000	1,11
13.06.2023	Sell	5 000	1,11

**14 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
13.06.2023	Buy	2 000,00	1,11
13.06.2023	Buy	10 000,00	1,11
13.06.2023	Buy	5 000,00	1,11
13.06.2023	Buy	5 000,00	1,11
13.06.2023	Buy	5 000,00	1,11
13.06.2023	Buy	5 000,00	1,11
13.06.2023	Buy	10 000,00	1,12
13.06.2023	Buy	5 000,00	1,11

13.06.2023	Buy	5 000,00	1,11
13.06.2023	Buy	8 000,00	1,11
13.06.2023	Buy	5 000,00	1,11
13.06.2023	Buy	5 000,00	1,11
13.06.2023	Buy	5 000,00	1,11
13.06.2023	Buy	5 000,00	1,11
13.06.2023	Buy	1 000,00	1,11

**14 June 2023**

### NOTIFICATION

"Sopharma" AD informs that according to Art. 3 § 26a and Art. 19 § 1 a received a notification from Rositsa Doneva, a person closely related to Ognian Ivanov Donev, that Mrs. Doneva carried out the following transactions with shares of "Sopharma" AD:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
13.06.2023	Buy	3 000	1,11

**14 June 2023**

### Conclusion of transactions from the scope of art. 114, para. 2 of the LPOS

Sofia, Bulgaria, 14 June 2023 – According to the requirements of Art. 100t of LPOS and in connection with Art. 114, para. 9 of the Law on Public Offering of Securities, "Sopharma" AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) announces that today, according to a decision of the Board of Directors dated 12 May 2023, the company concluded the following transaction falling within the scope of Art. 114, para. 2 of the LPOS:

1. "Sopharma" AD, UIC 831902088, as the seller, concluded a contract for the transfer of the right of ownership of real estate with the address Sofia, "Studentski" district, "St. Kliment Ohridski" № 3, with an area of 17,688 square meters with "Sopharma Buildings" REIT, UIC 175346309.

A) Participation of interested parties:

Ognian Donev - representing the public company "Sopharma" AD as a party to the transaction, directly and indirectly owns more than 25% of the capital of "Sopharma Buildings" REIT - counterparty to the transaction - grounds for interest under Art. 114, paragraph 7, item 2 of the LPOS;

B) Value of the transaction:

According to Art. 114, para. 5, ex. 1, item 2 of the LPOS, the value of the transferred property under Art. 114, para. 1, item 1 of the Civil Procedure Code is the higher between its market price and its value according to the last audited financial report of the company, which was publicly disclosed in accordance with Art. 100t.

The market price of the transferred property is determined according to a market valuation prepared by an independent appraiser under Art. 5 of the Law on Independents. According to the market valuation prepared in this way, the market value of the appraised real estate is BGN

6,308,920, not including corrections for taxes payable by one or the other party as a direct consequence of a possible transaction with the appraised object, incl. and VAT.

The value of the transferred property according to the last audited financial report of the company, which was publicly disclosed in accordance with Art. 100t from the LPOS, is BGN 4,840,788.

Therefore, on the basis of Art. 114, para. 5 of the LPOS, the value of the transferred property within the meaning of Art. 114, para. 5, ex. 1, item 2 of the LPOS is in the amount of BGN 6,308,920, as this is the higher of the two values.

The sale price agreed by the parties for the transaction is BGN 6,337,350 excluding VAT.

C) Assessment of the applicability of the conditions under Art. 114, para. 1, item 1 of the LPOS: The value of the described transaction does not exceed the threshold under Art. 114, para. 1, item 1 b. b) of the LPOS, due to which the transaction falls within the scope of Art. 114, para. 2 of LPOS and for its conclusion prior approval has been received by the Board of Directors of „Sopharma“ AD.

D) Assessment of the applicability of Art. 114 para. 6 of LPOS: With regard to this transaction, the hypothesis of Art. 114 para. 6 of the LPOS is not applicable.

**15 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
14.06.2023	Sell	3 000	1,11
14.06.2023	Sell	2 000	1,11
14.06.2023	Sell	1 000	1,11
14.06.2023	Sell	4 000	1,11
14.06.2023	Sell	1 000	1,11
14.06.2023	Sell	4 000	1,11
14.06.2023	Sell	1 000	1,11
14.06.2023	Sell	4 000	1,11
14.06.2023	Sell	1000	1,11
14.06.2023	Sell	4000	1,11
14.06.2023	Sell	5000	1,12
14.06.2023	Sell	5000	1,12

**15 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
14.06.2023	Buy	3 000,00	1,11
14.06.2023	Buy	2 000,00	1,11
14.06.2023	Buy	1 000,00	1,11
14.06.2023	Buy	4 000,00	1,11
14.06.2023	Buy	1 000,00	1,11
14.06.2023	Buy	4 000,00	1,11
14.06.2023	Buy	1 000,00	1,11
14.06.2023	Buy	4 000,00	1,11
14.06.2023	Buy	1 000,00	1,11
14.06.2023	Buy	4 000,00	1,11
14.06.2023	Buy	1 000,00	1,14
14.06.2023	Buy	5 000,00	1,12
14.06.2023	Buy	5 000,00	1,12
14.06.2023	Buy	2 000,00	1,12

**16 June 2023**

#### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
15.06.2023	Buy	100	5,60
15.06.2023	Buy	112	5,58
15.06.2023	Buy	100	5,60
15.06.2023	Buy	88	5,58
15.06.2023	Buy	200	5,56
15.06.2023	Buy	100	5,60

**16 June 2023**

#### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
15.06.2023	Sell	260	5,60

15.06.2023	Sell	40	5,58
15.06.2023	Sell	110	5,60
15.06.2023	Sell	300	5,58

**16 June 2023**

### NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
15.06.2023	Buy	5 000	1,07
15.06.2023	Buy	8 200	1,07
15.06.2023	Buy	1 800	1,07
15.06.2023	Buy	10 000	1,07
15.06.2023	Buy	5 000	1,07
15.06.2023	Buy	5 000	1,07
15.06.2023	Buy	10 000	1,07
15.06.2023	Buy	5 000	1,06
15.06.2023	Buy	9 896	1,06
15.06.2023	Buy	104	1,06
15.06.2023	Buy	5 000	1,04
15.06.2023	Buy	3 300	1,04

**16 June 2023**

### NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
15.06.2023	Sell	130	1,11
15.06.2023	Sell	5 000	1,11
15.06.2023	Sell	5 000	1,11
15.06.2023	Sell	5 000	1,11
15.06.2023	Sell	38	1,15
15.06.2023	Sell	5 000	1,11
15.06.2023	Sell	5 000	1,11
15.06.2023	Sell	5 000	1,11
15.06.2023	Sell	5 000	1,11
15.06.2023	Sell	4 000	1,11
15.06.2023	Sell	500	1,10
15.06.2023	Sell	3 000	1,10
15.06.2023	Sell	3	1,14
15.06.2023	Sell	1	1,14

**16 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
15.06.2023	Buy	5 000,00	1,11
15.06.2023	Buy	5 000,00	1,11
15.06.2023	Buy	5 000,00	1,11
15.06.2023	Buy	1 000,00	1,14
15.06.2023	Buy	5 000,00	1,11
15.06.2023	Buy	5 000,00	1,11
15.06.2023	Buy	5 000,00	1,11
15.06.2023	Buy	5 000,00	1,11
15.06.2023	Buy	4 000,00	1,11
15.06.2023	Buy	3 000,00	1,10
15.06.2023	Buy	3 000,00	1,07

**19 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
16.06.2023	Sell	900	1,05
16.06.2023	Sell	3 000	1,05
16.06.2023	Sell	3 000	1,05
16.06.2023	Sell	2 100	1,05
16.06.2023	Sell	900	1,05
16.06.2023	Sell	6 000	1,04
16.06.2023	Sell	500	1,04

**19 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:



<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
16.06.2023	Buy	2 000,00	1,06
16.06.2023	Buy	3 000,00	1,05
16.06.2023	Buy	3 000,00	1,05
16.06.2023	Buy	2 100,00	1,05
16.06.2023	Buy	900,00	1,05
16.06.2023	Buy	2 000,00	1,10
16.06.2023	Buy	410,00	1,10
16.06.2023	Buy	590,00	1,10
16.06.2023	Buy	960,00	1,10

**20 June 2023**

### **Sales revenues for May 2023**

Sofia, Bulgaria, June 20, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for the month of May 2023, "Sopharma" AD realized a decrease in sales of 13% compared to the same month of the previous year, including 24% decrease of domestic sales and 6% decrease of export sales.

For the five months of 2023, sales increased by a total of 15% incl. 6% decrease of sales for the domestic market and 32% increase in export sales.

**20 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
19.06.2023	Sell	262	5,56
19.06.2023	Sell	1000	5,54

**20 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
19.06.2023	Sell	5 000	1,04
19.06.2023	Sell	5 000	1,04
19.06.2023	Sell	4 000	1,03
19.06.2023	Sell	1 000	1,03
19.06.2023	Sell	1 000	1,02

19.06.2023	Sell	1 000	1,02
19.06.2023	Sell	4 000	1,07
19.06.2023	Sell	2 000	1,05
19.06.2023	Sell	2 000	1,05

**20 June 2023**

### NOTIFICATION

"Sopharma" AD informs that according to Art. 3 § 26a and Art. 19 § 1 a received a notification from Rositsa Doneva, a person closely related to Ognian Ivanov Donev, that Mrs. Doneva carried out the following transactions with shares of "Sopharma" AD:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
19.06.2023	Buy	900	1,09
19.06.2023	Buy	1 900	1,09
19.06.2023	Buy	2 200	1,09
19.06.2023	Buy	1 600	1,09
19.06.2023	Buy	3 400	1,09
19.06.2023	Buy	400	1,09
19.06.2023	Buy	1 057	1,09
19.06.2023	Buy	2 739	1,09
19.06.2023	Buy	804	1,09
19.06.2023	Buy	1 000	1,09
19.06.2023	Buy	4 000	1,07
19.06.2023	Buy	1 000	1,09
19.06.2023	Buy	2 000	1,05

**20 June 2023**

### NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
19.06.2023	Buy	5 000,00	1,04
19.06.2023	Buy	5 000,00	1,04
19.06.2023	Buy	4 000,00	1,03
19.06.2023	Buy	1 000,00	1,11
19.06.2023	Buy	2 000,00	1,10
19.06.2023	Buy	1 000,00	1,03
19.06.2023	Buy	1 000,00	1,02
19.06.2023	Buy	1 000,00	1,02
19.06.2023	Buy	900,00	1,09

19.06.2023	Buy	100,00	1,09
19.06.2023	Buy	1 000,00	1,09
19.06.2023	Buy	240,00	1,07
19.06.2023	Buy	2 000,00	1,05

**21 June 2023**

### NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
20.06.2023	Sell	3	5,50
20.06.2023	Sell	350	5,44
20.06.2023	Sell	100	5,44
20.06.2023	Sell	23	5,44
20.06.2023	Sell	78	5,32
20.06.2023	Sell	300	5,30
20.06.2023	Sell	1 000	5,30
20.06.2023	Sell	100	5,30
20.06.2023	Sell	157	5,30
20.06.2023	Sell	43	5,30
20.06.2023	Sell	150	5,30
20.06.2023	Sell	2	5,30

**21 June 2023**

### NOTIFICATION

"Sopharma" AD informs that according to Art. 3 § 26a and Art. 19 § 1 a received a notification from Rositsa Doneva, a person closely related to Ognian Ivanov Donev, that Mrs. Doneva carried out the following transactions with shares of "Sopharma" AD:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
20.06.2023	Buy	7 000	1,00

**21 June 2023**

### NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
---	------------------	---------------------------	-------------------------

20.06.2023	Buy	200,00	1,11
20.06.2023	Buy	200,00	1,10
20.06.2023	Buy	200,00	1,10
20.06.2023	Buy	200,00	1,10
20.06.2023	Buy	200,00	1,09
20.06.2023	Buy	1 000,00	1,08
20.06.2023	Buy	1 000,00	1,08
20.06.2023	Buy	2 000,00	1,07
20.06.2023	Buy	1 000,00	1,05
20.06.2023	Buy	1 000,00	1,04
20.06.2023	Buy	1 000,00	1,04
20.06.2023	Buy	200,00	1,00
20.06.2023	Buy	1 000,00	0,99
20.06.2023	Buy	2 000,00	0,96
20.06.2023	Buy	1 561,00	0,96
20.06.2023	Buy	439,00	0,96
20.06.2023	Buy	3 000,00	1,04

**22 June 2023**

### NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
21.06.2023	Sell	1 000	5,36
21.06.2023	Sell	1 000	5,36
21.06.2023	Sell	2 000	5,36
21.06.2023	Sell	5 000	5,38
21.06.2023	Sell	2 000	5,38
21.06.2023	Sell	180	5,38
21.06.2023	Sell	4 500	5,38
21.06.2023	Sell	320	5,38
21.06.2023	Sell	1 000	5,38
21.06.2023	Sell	300	5,30
21.06.2023	Sell	380	5,36
21.06.2023	Sell	300	5,30
21.06.2023	Sell	100	5,36
21.06.2023	Sell	20	5,36
21.06.2023	Sell	400	5,30
21.06.2023	Sell	400	5,36
21.06.2023	Sell	50	5,36
21.06.2023	Sell	500	5,36
21.06.2023	Sell	50	5,36
21.06.2023	Sell	250	5,36
21.06.2023	Sell	117	5,36

**21 June 2023**

## NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
21.06.2023	Buy	2000,00	0,95

**23 June 2023**

## NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
22.06.2023	Sell	200	5,36
22.06.2023	Sell	300	5,36
22.06.2023	Sell	5 000	5,34
22.06.2023	Sell	5 000	5,34
22.06.2023	Sell	5 000	5,34
22.06.2023	Sell	700	5,34
22.06.2023	Sell	500	5,32
22.06.2023	Sell	100	5,34
22.06.2023	Sell	200	5,34
22.06.2023	Sell	200	5,34

**26 June 2023**

## NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
23.06.2023	Sell	125	5,34

**27 June 2023**

## NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
26.06.2023	Sell	83	5,28
26.06.2023	Sell	140	5,28
26.06.2023	Sell	200	5,30

**27 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
26.06.2023	Sell	1 000	0,91
26.06.2023	Sell	10 000	0,91

**27 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mrs Bissera Lazarova, Member of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of warrants</b>	<b>Unit price (BGN)</b>
26.06.2023	Buy	10 000	0,91

**28 June 2023**

### **NOTIFICATION**

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
27.06.2023	Sell	1 000	5,34
27.06.2023	Sell	500	5,30
27.06.2023	Sell	5 000	5,30
27.06.2023	Sell	5 000	5,30
27.06.2023	Sell	100	5,30
27.06.2023	Sell	4 900	5,30
27.06.2023	Sell	5 000	5,30
27.06.2023	Sell	200	5,40
27.06.2023	Sell	10 000	5,36
27.06.2023	Sell	500	5,40
27.06.2023	Sell	10 000	5,36
27.06.2023	Sell	500	5,36
27.06.2023	Sell	100	5,36

27.06.2023	Sell	400	5,36
27.06.2023	Sell	200	5,30
27.06.2023	Sell	100	5,30

**28 June 2023**

### NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
28.06.2023	Buy	5 000,00	5,30
28.06.2023	Buy	5 000,00	5,30
28.06.2023	Buy	4 900,00	5,30
28.06.2023	Buy	5 000,00	5,30
28.06.2023	Buy	10 000,00	5,36
28.06.2023	Buy	10 000,00	5,36
28.06.2023	Buy	100,00	5,36

**29 June 2023**

### NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Price(s)	volume(s)
5,34	5 000
5,34	10 000
5,36	5 000
5,36	10 000
5,36	20 000
5,36	100 000
5,36	5 000
5,36	4 977
5,36	23

**29 June 2023**

### NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

Price(s)	volume(s)
5,34	5 000,00
5,34	10 000,00
5,36	200,00

5,36	300,00
5,36	200,00
5,36	5 000,00
5,36	10 000,00
5,36	20 000,00
5,36	500,00
5,36	100 000,00
5,36	5 000,00
5,34	23,00
5,36	4 977,00
5,36	23,00
5,36	77,00

**30 June 2023**

### NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Price(s)	volume(s)
5,40	5 000
5,40	50 000
5,40	5 000
5,40	20 000
5,40	5 000
5,40	5 000
5,40	200
5,40	800
5,40	5 000
5,40	10 000
5,40	500
5,40	9 500
5,40	223
5,40	200
5,36	100

**30 June 2023**

### NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

Price(s)	volume(s)
5,36	107,00
5,40	5 000,00
5,40	50 000,00
5,40	5 000,00
5,40	20 000,00
5,40	5 000,00
5,40	5 000,00
5,40	10 000,00
5,40	500,00
5,40	9 500,00
5,40	223,00
5,40	200,00



